ALSFRS-R

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue SUPPL. 1, 2004, Pages 90-93

  Gordon, Paul H ^a   Miller, Robert G ^b   Moore, Dan H ^b  

^a NEUROLOGICAL INSTITUTE   (United States)

^b NONE

Author keywords

ALS; Clinical trials; Functional rating scale

Indexed keywords

MINOCYCLINE;

ACCURACY; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CORRELATION ANALYSIS; COST CONTROL; DISEASE COURSE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; LUNG FUNCTION; MORTALITY; MUSCLE MASS; MUSCLE STRENGTH; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RATING SCALE; STANDARDIZATION; SURVIVAL RATE; VALIDATION PROCESS;

ACTIVITIES OF DAILY LIVING; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 6444224622     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/17434470410019906     Document Type: Article

References (15)

1. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-164.
2. Siesling S, van Vugt JP, Zwinderman KA, Kiebertz K, Roos RA. Unified Huntington's disease rating scale: a follow-up. Mov Disord 1998; 13: 915-919.
3. Farlow MR, Hake A, Messina J, Hartmann R, Veach J, Anand R. Response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001; 58: 417-422.
4. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996; 53: 141-147.
5. Hillel Ad, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic Lateral Sclerosis Severity Scale. Neuroepidemiology 1989; 8: 142-150.
6. ALS CNTF Treatment Study (ACTS) Group. A double-blind, placebo controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46: 1244-1249.
7. Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 1997; 152 (Suppl 1): S1-9.
8. Kasarskis EJ, Dey S, Berryman S et al. Anthropmetrics in the assessment of muscle atrophy in amyotrophic lateral sclerosis. Neurology 1998; 50(Suppl 1): A429.
9. Pioro EP, Majors A, Mitsumoto H. Proton magnetic resonance imaging reveals in vivo evidence of neurodegeneration and elevated glutamate in the medulla of patients with ALS. Neurology 1998; 50(Suppl 1): A315.
10. BDNF Study Group. A controlled trial of recombinant-methionyl BDNF (r-metHuBDNF) in ALS. Neurology 1999; 46: 1427-1433.
11. Cedarbaum JM, Stambler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase II/III). J Neurol Sci 1999; 169: 13-21.
12. Roilke KA, Peper SM, Houdek AM et al. Amyotrophic lateral sclerosis telemedicine clinical evaluations. Validation of ALS clinimetrics: ALS functional rating scale, ALS functional rating scale revised, and timed functional tests of bulbar and respiratory function cross-sectionally and longitudinally. Educational poster, University of Wisconsin Hospital.
13. Miano B, Bromberg MB. Variability in ALS functional rating scale scores. In Preparation, 2003.
14. Miller RG, Moore D, Barohn RJ et al. Phase II/II/III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843-848.
15. Moore DH, Miller RG et al. ALSFRS as a measure of disease progression and a predictor of survival. In preparation, 2003.